Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Roche's experimental Parkinson's drug showed promise in early-stage patients, despite missing primary study goals.
Roche's experimental drug prasinezumab showed potential benefits for early-stage Parkinson's disease patients in a mid-stage study, despite failing to meet its main goal.
The drug, which targets proteins linked to Parkinson's, demonstrated positive trends in slowing motor decline and was well-tolerated.
Roche will consult with health authorities to determine next steps for the treatment.
4 months ago
13 Articles